Neurological conditions such as Parkinson’s disease and Alzheimer’s disease have long evaded satisfactory treatment. Despite the best efforts and the investment of billions by pharmaceutical companies, they continue to pose threats to public health - especially as life expectancies around the world increase and exposure to risk factors such as … [Read more...] about Parkinson’s and the difficulty of treating neurological conditions
In yet another setback to the treatment of Alzheimer’s disease, Axovant Sciences has announced that their latest attempt at creating a treatment - a drug known as Intepirdine (a (5-HT)6 receptor antagonist) - has failed during late stage clinical trials. Meanwhile, pharmaceutical giant Pfizer Inc has announced plans to leave the field of … [Read more...] about Axovant fails while Pfizer leaves – the grim outlook of Alzheimer’s research
Alzheimer’s research may see a well needed boost in the form of a research deal funded by Chicago based pharmaceutical group AbbVie. The recipient research group, Alector, is to receive a $205 million USD up front payment, as well as future equity investments worth up to $20 million. Alector has seen a great deal of interest within the … [Read more...] about Immunotherapy: the future of Alzheimer’s research?
A drug trial for a Merck & Co Inc. (MSD) medication verubecestat has been stopped because it was very unlikely to show a significant difference in Alzheimers disease progression compared to a placebo control. This was a phase III clinical trial in patients with early dementia. The setback comes after months of positive media attributed … [Read more...] about Failed trials for Alzheimer’s may mean a key theory is wrong